Dr. Jochen Beninga, Sanofi, Frankfurt, Germany
SAR156597, an engineered bispecific antibody, simultaneously binds both IL-4 and IL-13 with high affinity and may attenuate the pathogenesis of idiopathic pulmonary fibrosis, a severe disease with few therapeutic options and a mean survival time of 3 years. This talk will describe the generation of SAR156597 as case study for multispecific biotherapeutics an area that has seen tremendous advances in the last years.